(Refiles to correct formatting of bullets)
April 3 (Reuters) - Rigel Pharmaceuticals Inc:
* RIGEL ANNOUNCES TOPLINE DATA FROM PROOF-OF-CONCEPT PHASE 2 STUDY OF FOSTAMATINIB IN IGA NEPHROPATHY
* TRIAL DID NOT ACHIEVE STATISTICAL SIGNIFICANCE FOR ITS PRIMARY ENDPOINT
* ‍FOSTAMATINIB WAS WELL TOLERATED WITH MOSTLY MILD TO MODERATE ADVERSE EVENTS​
* FURTHER ANALYSIS OF THE TREATMENT, INCLUDING HISTOLOGY, ARE EXPECTED LATER IN YEAR
* ‍THERE WERE NO NEW SAFETY SIGNALS COMPARED TO FOSTAMATINIB’S SAFETY DATABASE ACROSS ALL INDICATIONS​
* PATIENTS WITH GREATER THAN 1 GRAM/DAY OF PROTEINURIA HAVE AN INCREASED RISK OF DISEASE PROGRESSION AND REPRESENT AN UNMET MEDICAL NEED
* ‍RIGEL PLANS TO SEEK A PHARMACEUTICAL PARTNER TO COLLABORATE IN CONDUCT OF FOLLOW-ON CLINICAL STUDIES IN IGAN​
* PHARMACEUTICAL​ PARTNER WOULD TAKE RESPONSIBILITY FOR SUBSEQUENT COMMERCIALIZATION OF FOSTAMATINIB IF IN AN EX-U.S. TERRITORY Source text for Eikon: Further company coverage:
